31.1 C
New York
Saturday, June 13, 2026

Tag: fatigue

newssourceFORcompanyinformationcontent1marketreleases

The Power of Massage Therapy for Autoimmune Diseases: AMTA Highlights Emerging Research

EVANSTON, Ill., July 23, 2025 /PRNewswire/ -- The American Massage Therapy Association (AMTA) is committed to advancing integrative health care by spotlighting the powerful role...

Ready or Not: Most HR Leaders Say They’re Prepared for Change–Are Their Organizations?

NEW YORK, July 22, 2025 /PRNewswire/ -- From rapid advances in AI to geopolitical volatility and evolving workforce expectations, organizations are facing historic levels...

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a standard review procedure, potentially supporting approval of the vaccine in the first half of 2026.

Industrial Floor Mats Market Size to Grow USD 3987.1 Million by 2030 at a CAGR of 2.3% | Valuates Reports

BANGALORE, India, July 21, 2025 /PRNewswire/ -- Industrial Floor Mats Market is Segmented by Type (Anti-fatigue Mats, Anti-static Mats, Traction Mats, Non-conductive Mats), by...

Natural Appetite Suppressant: Why More Are Choosing PhenQ Over Weight Loss Injections for Safer Weight Management Results in 2025

New York City, NY, July 21, 2025 (GLOBE NEWSWIRE) -- PhenQ is leading the 2025 weight loss revolution with a science-backed natural appetite suppressant—no needles, no harsh side effects, just sustainable, healthy weight control

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – –...

Workout Routine For Men Revealed: How To Build Muscle Fast With CrazyBulk Muscle Gaining Supplements

Discover the ultimate workout routine for men and learn how to build muscle fast with expert training tips, CrazyBulk stacks, and muscle gaining supplements. Get actionable strategies and science-backed advice for rapid results, maximum strength, and a lean, powerful physique. 
Discover the ultimate workout routine for men and learn how to build muscle fast with expert training tips, CrazyBulk stacks, and muscle gaining supplements. Get actionable strategies and science-backed advice for rapid results, maximum strength, and a lean, powerful physique.

The Pink Salt Trick Recipe for Fast Weight Loss Trend in 2025: Why ProZenith Is the Science-Backed Alternative

Explore the Science Behind ProZenith’s Non-Stimulant Metabolic Support 
Explore the Science Behind ProZenith’s Non-Stimulant Metabolic Support

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms – 
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast

Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025. 
Explore how CrazyBulk legal muscle building supplements power muscle gain, improve muscle strength, and unlock next-level muscle performance in 2025.

Roundhouse Provisions Basecamp Complete Wins “Meal Replacement Product of the Year” at 2025 Mindful Awards

Plant-Based, Chuck Norris-Approved Nutrition Shake Recognized for Exceptional Convenience, Taste, and Nutritional Balance HOUSTON, July 18, 2025 /PRNewswire/ -- Roundhouse Provisions®, the trusted wellness brand...

PhenQ – Round the Clock Weightloss: 2025’s Strongest 24/7 Fat-Burning System for Appetite Control, Sleep-Supported Metabolism & Craving Relief

2025’s Strongest 24/7 Fat-Burning System for Appetite Control, Sleep-Supported Metabolism & Craving Relief 
2025’s Strongest 24/7 Fat-Burning System for Appetite Control, Sleep-Supported Metabolism & Craving Relief

Pacuzzi Releases 2025 Pacuzzi Skillet Steamer Innovation Amid Surging Demand for Multi-Use Cookware

This release explores how Pacuzzi’s 2025 cookware model delivers on the rising need for modular, space-saving tools that support healthier cooking and efficient kitchens. 
This release explores how Pacuzzi’s 2025 cookware model delivers on the rising need for modular, space-saving tools that support healthier cooking and efficient kitchens.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFatigue

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers